P16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas

Triple-negative breast carcinomas represent a tumor group of pivotal clinical importance given the lack of target therapies. The prognostic significance of triple-negative breast carcinomas remains unclear because of their histological and molecular heterogeneity. Currently, neither prognostic nor p...

Full description

Saved in:
Bibliographic Details
Published in:Modern pathology 2014-02, Vol.27 (2), p.204-213
Main Authors: Bogina, Giuseppe S, Lunardi, Gianluigi, Marcolini, Lisa, Brunelli, Matteo, Bortesi, Laura, Marconi, Marcella, Coati, Francesca, Valerio, Matteo, Guerriero, Massimo, Massocco, Alberto, Pegoraro, Maria C, Zamboni, Giuseppe
Format: Article
Language:English
Subjects:
692/699/67/1059/99
692/699/67/1347
692/700/1750
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - analysis
Breast cancer
Cancer therapies
Chemotherapy
Clinical outcomes
Cyclin-Dependent Kinase Inhibitor p16 - biosynthesis
Cyclin-dependent kinases
Disease-Free Survival
Female
Humans
Hybridization
Immunohistochemistry
Kinases
Laboratory Medicine
Medical prognosis
Medicine
Medicine & Public Health
Middle Aged
Oncology
original-article
p16
Pathology
Prognosis
Protein expression
Proteins
Retinoblastoma
Retinoblastoma Protein - biosynthesis
Triple Negative Breast Neoplasms - metabolism
Triple Negative Breast Neoplasms - mortality
triple-negative breast cancer
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Triple-negative breast carcinomas represent a tumor group of pivotal clinical importance given the lack of target therapies. The prognostic significance of triple-negative breast carcinomas remains unclear because of their histological and molecular heterogeneity. Currently, neither prognostic nor predictive factors are available for these tumors. Retinoblastoma (Rb) pathway loss has been linked to clinical outcome in various cancer types, including breast cancer. We investigated the association between Rb and p16 protein expression and clinical outcome in no-special-type triple-negative breast carcinomas. Immunohistochemical staining for Rb, p16, p53 and CK5 was carried out on a section from archival specimens of 117 no-special-type triple-negative breast carcinomas. Immunopositive p16 (p16+) and immunonegative Rb (Rb−) staining were seen in 49.5% and in 24.8% of tumors, respectively. There was an inverse correlation between p16+ and Rb− (P
ISSN:0893-3952
1530-0285
DOI:10.1038/modpathol.2013.137